+Compare
SBFM
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
6.32M

SBFM Sunshine Biopharma Forecast, Technical & Fundamental Analysis

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for SBFM with price predictions
07:00 PM EST Dec 06, 2023

SBFM's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SBFM turned positive on November 24, 2023. Looking at past instances where SBFM's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 28, 2023. You may want to consider a long position or call options on SBFM as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBFM advanced for three days, in of 150 cases, the price rose further within the following month. The odds of a continued upward trend are .

SBFM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 27 cases where SBFM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SBFM entered a downward trend on December 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.314) is normal, around the industry mean (47.989). P/E Ratio (0.877) is within average values for comparable stocks, (60.542). SBFM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.883). SBFM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.317) is also within normal values, averaging (65.502).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SBFM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBFM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NASDAQ:ZTS), Teva Pharmaceutical Industries Limited (NASDAQ:TEVA), Elanco Animal Health (NASDAQ:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NASDAQ:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.76B. The market cap for tickers in the group ranges from 246 to 82.08B. ZTS holds the highest valuation in this group at 82.08B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was -5%. UPC experienced the highest price growth at 68%, while CNTRF experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 53
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

SBFM is expected to report earnings to rise 50.00% to -5 cents per share on April 03

Sunshine Biopharma SBFM Stock Earnings Reports
Q4'23
Est.
$-0.06
Q3'23
Beat
by $0.02
Q2'23
Beat
by $0.06
The last earnings report on November 13 showed earnings per share of -3 cents, beating the estimate of -5 cents. With 53.51K shares outstanding, the current market capitalization sits at 6.32M.
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
6500 Trans-Canada Highway
Phone
+1 514 426-6161
Employees
83
Web
https://www.sunshinebiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NGL4.260.07
+1.67%
NGL Energy Partners LP
TWLO68.780.48
+0.70%
Twilio
CAAS3.67-0.03
-0.81%
China Automotive Systems
DGLY1.82-0.02
-1.36%
Digital Ally
VYX15.48-0.26
-1.65%
NCR Voyix Corp

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ORGO have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ORGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
+2.07%
ORGO - SBFM
27%
Poorly correlated
-1.92%
SUPN - SBFM
22%
Poorly correlated
+1.83%
SIGA - SBFM
21%
Poorly correlated
+4.80%
RDHL - SBFM
21%
Poorly correlated
-3.08%
TARO - SBFM
21%
Poorly correlated
+0.71%
More

Groups containing SBFM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
+2.07%
Pharmaceuticals
(undefined stocks)
-4%
Poorly correlated
-0.02%
Pharmaceuticals: Other
(undefined stocks)
-4%
Poorly correlated
+0.02%